Tinkeso Therapeutics

Advancing NKT cell therapies for cancers and autoimmune disorders

Valhalla, United States · Founded 2016 · $600K raised

Headquarters
Valhalla
Employees
1–10
Founded
2016
Business Model
B2B
Total Funding
$600K
Last Round
$600K Venture RoundSep 2024
Rounds
1

About

Tinkeso Therapeutics (formerly Akeso Therapeutics) is an early-stage biotechnology company based in Valhalla, New York, dedicated to advancing Natural Killer T (NKT) cell therapies for the treatment of cancers and autoimmune disorders. Founded in 2016, the company's pipeline covers both native and engineered NKT cell therapies. Its lead asset, IMK-101, is an engineered invariant NKT (iNKT) cell therapy targeting several types of leukemia. Operating from BioInc@NYMC in Valhalla, Tinkeso aims to address unmet patient needs with off-the-shelf, allogeneic cell therapy solutions.

Summary

Tinkeso Therapeutics is a Biotech company based in Valhalla, United States, founded in 2016. It has raised $600K in total across 1 round, most recently a $600K Venture Round round in Sep 2024. Investors include IndieBio and SOSV.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundSep 2024
$600K

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tinkeso Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/tinkeso-therapeutics"><img src="https://indexed.vc/api/badge/company/tinkeso-therapeutics" alt="Tinkeso Therapeutics on Indexed.vc" width="260" height="76" /></a>